For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | - | - | - | 0 |
| Research and development | 131,096,000 | 208,021,000 | 51,265,000 | 41,127,500 |
| Acquired in-process research and development | 0 | 0 | - | 3,751,750 |
| General and administrative | 103,115,000 | 360,416,000 | 15,586,000 | 14,437,000 |
| Impairment of intangible assets | - | - | - | 6,502,750 |
| Total operating expenses | 234,211,000 | 568,437,000 | 66,851,000 | 65,819,000 |
| Other operating income, net | - | - | - | 205,000 |
| Operating loss | - | - | - | -65,614,000 |
| Other income, net | 2,418,000 | 2,729,000 | 3,938,000 | 13,097,000 |
| Interest expense | 0 | 0 | 0 | 2,171,500 |
| Net loss | -231,793,000 | -565,708,000 | -62,913,000 | -61,203,000 |
| Foreign currency translation adjustments | 43,000 | -189,000 | -145,000 | 135,000 |
| Reclassification of unrealized loss on short-term investments to other expense, net | 0 | 0 | - | 0 |
| Reclassification of cumulative currency translation gain to other expense, net | - | - | - | 0 |
| Unrealized gain (loss) on short-term investments | 0 | 0 | -133,000 | -100,500 |
| Comprehensive loss | -231,750,000 | -565,897,000 | -63,191,000 | -61,280,000 |
| Basic (in dollars per share) | -0.31 | -0.76 | -0.09 | -0.08 |
| Basic (in shares) | 743,415,917 | 742,615,007 | 738,076,003 | -1,417,804,042 |
| Diluted (in dollars per share) | -0.31 | -0.76 | -0.09 | -0.08 |
| Diluted (in shares) | 743,415,917 | 742,615,007 | 738,076,003 | -1,417,804,042 |
Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (SMMT)